A federal judge in the Eastern District of Pennsylvania has denied class certification to wholesalers of the narcolepsy drug Provigil who claimed that its maker, Cephalon, paid off Ranbaxy Laboratories to delay generic versions of the medication from entering the market.
U.S. District Judge Mitchell S. Goldberg of the Eastern District of Pennsylvania’s ruling comes nearly a year after the U.S. Court of Appeals for the Third Circuit revoked class status in the case and sent it back to Goldberg for a second look.
